OROPHARYNGEAL CANCER

This study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…

This trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also rec…

This early-phase study tested a shorter, more intense radiation schedule (completed in 3 weeks instead of the usual 6) combined with chemotherapy for people with HPV-related throat cancer. The goal was to find the safest dose that still controls the cancer. Only 24 patients took …

This study collected speech recordings from 501 people, including those with oral or oropharyngeal cancer and healthy volunteers. Researchers are developing AI models to analyze voice patterns and detect cancer early. The goal is to create a non-invasive, low-cost screening tool.

This study tested whether shining a red LED light on mouth sores caused by radiation therapy can help them heal. 28 people with head or neck cancer who already had mild sores received a 7-minute light treatment before each radiation session. The main goal was to see if the sores …

This completed study looked at whether circulating tumor cells (CTCs) in the blood can help predict or detect early return of oropharyngeal cancer. Researchers took blood samples from 12 patients at different times (diagnosis, after treatment, and during follow-up) and analyzed t…

This study tested whether a mathematical model could help doctors choose the best radiation schedule for people with HPV-positive throat cancer. The goal was to see if personalized dosing could shrink tumors faster than standard treatment. Fifty-five adults took part, and researc…